CD5 antibody is a T-cell associated marker that is also expressed by two B-cell neoplasms: lymphocytic leukemia and mantle cell lymphoma. CD5 antigen is expressed in 95% of thymocytes and 72% of peripheral blood lymphocytes. It has been shown to react with thymic carcinomas, but rarely in thymomas. It has also been observed in a subset of intravascular large B-cell lymphomas and marks some anaplastic large cell lymphomas. CD5 has been reported to be very useful in marking mantle cell lymphoma when used in tandem with CD23, cyclin D1, and CD10 (CD10 is negative; CD5 and cyclin D1 are positive for mantle cell lymphoma).
1. Baseggio L, et al. Haematologica. 2010 Apr; 95(4):604-12.
2. Belaud-Rotureau MA, et al. Mod Pathol. 2002 May; 15(5):517-25.
3. Tateyama H, et al. Am J Clin Pathol 1999 Feb; 111(2):235-40.
4. de Leon ED, et al. Mod Pathol 1998 Nov; 11(11):1046-51.
5. Khalidi HS, et al. Mod Pathol 1998 Oct; 11(10):983-8.
6.Kaufmann O, et al. Am J Clin Pathol 1997 Dec; 108(6):669-73.